Adoptive t-cell therapy for b-cell malignancies

Michael Hudecek, Larry D. Anderson, Tetsuya Nishida, Stanley R. Riddell

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.

Original languageEnglish (US)
Pages (from-to)517-532
Number of pages16
JournalExpert Review of Hematology
Issue number5
StatePublished - 2009


  • Adoptive T-cell therapy
  • Allogeneic hematopoietic cell transplantation
  • Central memory T cell
  • Chimeric antigen receptor
  • Graft-versus-host disease
  • Graft-versus-tumor effect
  • Immunoglobulin idiotype
  • Minor histocompatibility antigen
  • T-cell receptor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Adoptive t-cell therapy for b-cell malignancies'. Together they form a unique fingerprint.

Cite this